With remdesivir, the Federal Joint Committee assesses the additional benefit of an anti-viral COVID-19 drug for the first time

16 September 2021 - Do patients with COVID-19 have a better chance of surviving and recovering faster if they are treated ...

Read more →

Nivolumab in skin cancer: additional benefit upgraded on the basis of an indirect comparison

16 September 2021 - For nivolumab (Opdivo), the pharmaceutical company was able to achieve a significantly better result in a second ...

Read more →

Venetoclax in acute myeloid leukaemia: indication of a considerable added benefit

15 September 2021 - Third new area of ​​application/those affected still live a good year on average - and thus ...

Read more →

Method paper: IQWiG puts draft version 6.1 up for discussion

23 August 2021 - The IQWiG has presented the draft for the next version of its General Methods.  ...

Read more →

Spinal muscular atrophy: second and third active ingredients undergo benefit assessment

16 August 2021 - With risdiplam there is a hint of an added benefit for spinal muscular atrophy type 1, ...

Read more →

Lanadelumab in hereditary angioedema: added benefit not proven

16 August 2021 - The active ingredient has exceeded the sales limit for the simplified orphan drug assessment. There are no ...

Read more →

Quality assurance requirements of the G-BA also apply to new CAR-T cell therapy

5 August 2021 - The Federal Joint Committee (G-BA) today evaluated the new cancer drug with the trade name Tecartus and ...

Read more →

G-BA sees “considerable additional benefit” in two active ingredients - EU HTA analysis is coming

15 July 2021 - The Federal Joint Committee (G-BA) today certified two active ingredients with a "considerable additional benefit". It assigns ...

Read more →

Remdesivir in COVID-19: indication of considerable added benefit for a part of the patients

1 July 2021 - COVID-19 patients with pneumonia who do not yet require high-flow oxygen therapy benefit from remdesivir: they recover ...

Read more →

German law makers seek to ease reimbursement for advanced therapies

15 June 2021 - Advanced therapy trade group The Alliance for Regenerative Medicine has highlighted the passage of a new ...

Read more →

Bluebird’s withdrawal of therapy from Germany could chill talks over gene therapy prices across Europe

22 April 2021 - When Bluebird Bio secured European approval for its gene therapy to treat beta thalassaemia in 2019, ...

Read more →

Novartis to discontinue sales of Piqray in Germany

21 April 2021 - The sale of Piqray (alpelisib) will be discontinued by Novartis in accordance with Section 4 (7) ...

Read more →

Germany to restrict AstraZeneca use in under-60s over clots

30 March 2021 - German health officials have agreed to restrict the use of AstraZeneca’s coronavirus vaccine in people under 60, ...

Read more →

Early benefit assessment - the whole spectrum

19 March 2021 - IQWiG evaluated a total of 24 manufacturer dossiers punctually for the dates March 1 and March 15.  ...

Read more →

Nusinersen in spinal muscular atrophy: indication of considerable added benefit in children with an early onset of the disease

1 March 2021 - The treatment delays permanent ventilation of the children and extends life. In addition, the children develop more ...

Read more →